RAPT Therapeutics Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
RAPT Therapeutics (RAPT) Prices 3.79M Common Stock Offering at $33/Sh
June 16, 2021 6:17 AM EDTRAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 3,787,879 shares of its common stock at a price to the public of $33.00 per share. All of the shares of common stock are being offered by RAPT. Gross proceeds to RAPT from the offering are expected to be approximately $125 million,... More
RAPT Therapeutics (RAPT) Adds to Intra-Day Gains Despite Stock Offering; Last Up 23%
June 14, 2021 5:46 PM EDTRAPT Therapeutics (NASDAQ: RAPT) is adding to its intra-day gains despite announcing a $125 million share stock offering.
Shares are up 22.5% after-hours after gaining 115% intra-day on positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).
... More